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Abstract: The prevalence of diabetes is increasing globally, and its effect on patients and the 
healthcare system can be significant. Gestational diabetes mellitus (GDM) and type 2 diabetes are 
well established risk factors for cardiovascular disease, and strategies for managing these conditions 
include dietary interventions, such as the use of a low glycemic index (GI) diet. Aims: This review 
aimed to evaluate the effects of a low GI diet on the cardio-metabolic and inflammatory parameters 
in patients with type 2 diabetes and women with GDM and assess whether the effects are different 
in these conditions. Methods: This review was based on the preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) guidelines. Three databases (EMBASE, Pubmed, and 
PsycINFO) were searched from inception to 20 February 2019 using search terms that included 
synonyms and Medical Subject Headings (MeSH) in line with the population, intervention, 
comparator, outcomes, and studies (PICOS) framework. Studies were evaluated for the quality and 
risk of bias. Results: 10 randomised controlled studies were included in the systematic review, while 
9 were selected for the meta-analysis. Two distinct areas were identified: the effect of a low GI diet 
on lipid profile and the effect of a low GI diet on inflammatory parameters. The results of the meta-
analysis showed that there were no significant differences (p > 0.05) between the low GI and higher 
GI diets with respect to total cholesterol, HDL, and LDL cholesterol in patients with type 2 diabetes. 
However, there was a significant difference (p = 0.027) with respect to triglyceride which increased 
by a mean of 0.06 mmol/L (0.01, 0.11) in patients with type 2 diabetes on higher GI diet. With respect 
to the women with GDM, the findings from the systematic review were not consistent in terms of 
the effect of a low GI diet on the lipid profile. The results of the meta-analysis did not show 
significant differences (p > 0.05) between low GI and higher GI diets with respect to adiponectin and 
C-reactive proteins in patients with type 2 diabetes, but a significant difference (p < 0.001) was 
observed between the two groups in relation to interleukin–6. Conclusion: This systematic review 
and meta-analysis have demonstrated that there were no significant differences (p > 0.05) between 
the low GI and higher GI diets in relation to total cholesterol—HDL and LDL cholesterol—in 
patients with type 2 diabetes. However, a significant difference (p < 0.05) was observed between the 
two groups with respect to triglyceride in patients with type 2 diabetes. The results of the effect of 
a low GI diet on the lipid profile in patients with GDM were not consistent. With respect to the 
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inflammatory parameters, the low GI diet significantly decreased interleukin–6 in patients with type 
2 diabetes compared to the higher GI diet. More studies are needed in this area of research. 
Keywords: type 2 diabetes; gestational diabetes; glycemic index; randomised controlled trial; lipid 
profile; inflammatory parameters 
 
1. Introduction 
Globally, there is an increasing prevalence of diabetes, with over 420 million people living with 
the condition. This number has significant implications for health care provisions due to the impact 
of diabetes and its complications on those who have the condition [1,2]. Type 2 diabetes is usually 
characterised by insulin deficiency due to beta cell dysfunction and often involves insulin resistance 
[3]. On the other hand, hyperglycaemia first detected at any time during pregnancy is classified either 
as diabetes in pregnancy or Gestational Diabetes Mellitus (GDM), and are usually diagnosed based 
on the fasting and/or 2 h plasma glucose following a 75 g oral glucose load [4]. 
Both type 2 diabetes and GDM have implications for carbohydrate, protein and fat metabolism 
and may predispose individuals to acute and long-term complications [5]. About half of the women 
diagnosed with GDM proceed to develop type 2 diabetes within 5 to 10 years after giving birth [6]. 
Due to changing lifestyles, type 2 diabetes is increasingly diagnosed in children [7]. In 2013, over 3.2 
million adults were diagnosed with diabetes in England and Wales, with prevalence rates of 6% and 
6.7% in England and Wales, respectively [7]. In addition, about 90% of adults who are currently 
diagnosed with diabetes have type 2 diabetes, with the burden of the disease disproportionally 
affecting ethnic minorities, particularly Africans, African-Caribbeans, and South Asians [7]. 
GDM presents adverse risks to the mother and child during the pre- and post–natal period [4]. 
It was estimated that 21.3 million live births had some form of raised blood glucose or 
hyperglycaemia in 2017, and about 85.1% of these were due to GDM [6]. This represented about one 
in every seven births affected by GDM [6]. In England and Wales, of the estimated 700,000 women 
who give birth every year, about 5% have either pre-existing diabetes or GDM [8]. About 87.5% of 
these women who have diabetes during pregnancy have GDM [8]. Therefore, management strategies, 
including dietary interventions such as the use of a low glycemic index (GI) diet, have been 
recommended instead of a higher GI diet, in order to manage hyperglycaemia and mitigate related 
complications [8]. In our previous review on the effect of a low GI diet in patients with type 2 diabetes, 
Ojo et al. [9] found that a low GI diet was more effective in controlling glycated haemoglobin and 
fasting blood glucose compared with a higher GI diet in these patients. Therefore, this current review 
builds on the earlier systematic review and meta-analysis [9] by assessing the impact of a low GI diet 
on lipid profile and inflammatory markers. 
Why is it important to do this review? GDM is closely associated with type 2 diabetes, as they 
share many key pathophysiological characteristics including progressive insulin resistance [3,10]. In 
addition, people who develop either type 2 diabetes or GDM have similar risk factors, such as 
ethnicity (South Asian or Afro–Caribbean), a high body mass index (BMI), family history, and 
advanced age [5,10]. 
Although low grade inflammation and insulin resistance are part of normal physiological 
adaptation of pregnancy, these processes are exacerbated in patients with GDM and obesity [11]. 
Elevated levels of inflammatory components, such as tumour necrosis factor alpha (TNF-α), have 
been shown to correlate with progressive insulin resistance in pregnancy and are associated with 
hyperinsulinaemia in obesity and in patients with type 2 diabetes [10]. The risks associated with 
GDM, including postpartum type 2 diabetes, increase with progressive hyperglycaemia [8,12]. 
Furthermore, both GDM and type 2 diabetes are well established risk factors for cardiovascular 
diseases [3,5,13]. 
This calls for scrutiny and a greater understanding of the role of low GI diets on inflammatory 
parameters and lipid profiles (cardiometabolic parameters) in these patients, as the biomarkers have 
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implications for insulin resistance and cardiovascular mortality. We know this based on the 
knowledge that dietary interventions are useful approaches to managing type 2 diabetes and GDM. 
Therefore, a study should involve an evaluation of the effect, and quality and quantity of the macro 
and micronutrients in the foods consumed. Of particular interest is the quality of carbohydrate in the 
diets of people with type 2 diabetes or GDM, often linked to its glycemic index (GI). Foods with low 
GI may improve glycemic control including the reduction in glycated haemoglobin (HbA1c) through 
improvement in peripheral insulin sensitivity [14–19]. However, the evidence regarding the effect of 
a low GI diet on lipid profiles is still conflicting. 
Bouchie et al. [20] revealed that 5 weeks of a low GI diet was useful in improving plasma lipids 
in non-diabetic men who were moderately overweight. However, in normolipidemic well controlled 
patients with type 2 diabetes, Brand et al. [21] observed that low GI diets did not provide 
improvement in plasma lipids. Clar et al. [22], in their meta–analysis, noted that there is, presently, 
no compelling evidence that shows that low GI diets have significant beneficial effects on blood 
lipids. On the other hand, Schwingshacki and Hoffman [23] demonstrated that a low GI diet has 
beneficial effects with respect to pro–inflammatory markers, such as C–reactive protein (CRP) which 
may be useful in preventing obesity associated diseases. This study involved both patients who had 
type 2 diabetes and participants who were non–diabetic. The systematic reviews by Goff et al. [13], 
Clar et al. [22], and Fleming and Godwin [24] were based on assessing the effect of low GI diets on 
lipid profiles on either general participants or those with cardiovascular diseases. No previous review 
has assessed the effect of a low GI diet on both lipids and the inflammatory profile of patients with 
type 2 diabetes and/or GDM. Therefore, the current review evaluates the impact of a low GI diet on 
the cardio-metabolic and inflammatory parameters in patients with type 2 diabetes and GDM. This 
is based on the understanding that the control of cardio-metabolic parameters is a useful approach 
in managing patients with type 2 diabetes and women with GDM [4,25]. 
Objectives: 
This is a systematic review and meta-analysis which: 
• Evaluates the effect of a low GI diet on cardio-metabolic and inflammatory parameters in 
patients with type 2 diabetes and women with GDM. 
2. Methods 
This systematic review and meta-analysis was written according to the preferred reporting items 
for systematic reviews and meta-analyses (PRISMA) guidelines [26]. The eligibility criteria for paper 
inclusion according to type of study, participants, intervention, and outcomes are described below. 
Types of Studies: 
Randomised controlled studies were the only studies included in this review (Tables 1 and 2). 
Type of Participants: 
Patients with type 2 diabetes or pregnant women with gestational diabetes were the participants 
of interest in all the studies selected (Table 2). 
Type of Interventions: 
Diets with low GI were compared with diets with higher GI in patients with type 2 diabetes and 
in women with GDM. The classification of diets as having either low GI or higher GI was based on 
the lower GI values of the intervention diets (low GI diet). 
2.1. Outcomes of Interest 
The primary measures of interest were: 
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• Cardio-metabolic parameters: total cholesterol (TC) mmol/L, low density lipoprotein (LDL) 
cholesterol mmol/L, high density lipoprotein (HDL) cholesterol mmol/L, and triglycerides (TG) 
mmol/L. 
The secondary outcome measures were: 
• Inflammatory parameters: C–reactive protein (CRP) mg/L, Adiponectin mg/L, and Interleukin–
6 (IL-6) mg/L. 
2.2. Search Terms and Search Strategy 
The process of searching for articles for this review relied on the Population, Intervention, 
Comparator, Outcome, and Study design (PICOS) approach [27] and involved electronic databases 
(EMBASE, Pubmed, and PsycINFO) from inception to 20 February 2019. A number of articles were 
identified through this process by using search terms, including Medical Subject Headings (MeSH) 
and synonyms. Boolean operators (AND/OR) were used to combine words and search terms (Table 
1). The reference lists of included articles were manually searched for relevant papers. 
2.3. Inclusion and Exclusion Criteria 
The criteria for selecting studies are outlined in Table 2. No time or language restriction was 
applied. Only primary research studies that were randomised controlled trials were selected for this 
review. In addition, studies involving patients with type 2 diabetes or GDM and the use of low GI 
diets across the world were included. Those studies not meeting the criteria set out in Table 2 and the 
text were excluded from this review. In this regard, studies that had animals, patients with type 1 
diabetes, children with diabetes, or healthy adults without diabetes were excluded from the current 
review (Table 2). In addition, observational studies and those involving dietary supplements were 
excluded. Therefore, a total of 9 studies were included in the meta-analysis (Figure 1). 
Table 1. Search Strategy and Search Terms. 
Population  Intervention Comparator Study Designs Combining Search Terms 
Patients with Diabetes  Low Glycemic Index (GI) Diet  
Higher GI 
Diet  
Randomised 
Controlled Trial  
Type 2 diabetes OR 
diabetes OR Patients with 
diabetes OR diabetes 
mellitus OR Gestational 
diabetes OR gestational 
diabetes mellitus (GDM) 
OR gestational diabetes 
mellitus OR diabetes 
mellitus, gestational OR 
diabetes in pregnancy  
GI diet OR 
glycemic index OR 
Glycemic Index 
Numbers OR 
glycemic load OR 
Glycemic Indices OR 
Glycemic Index 
Number  
 
#1 Controlled clinical 
trial OR Randomised 
controlled trial OR 
placebo OR 
randomized OR  
groups OR drug 
therapy OR randomly 
OR trial  
Column 1 
AND 
Column 2 
AND 
Column 3  
#2 “Animals” NOT 
“Humans” 
#3 #1 NOT #2 
Table 2. Inclusion and Exclusion Criteria Based on PICOS Framework. 
 Inclusion Criteria Exclusion Criteria 
Population 
Patients with gestational diabetes or patients 
with type 2 diabetes 
Studies involving participants with 
type 1 diabetes and animal studies.  
Studies that include children that 
have diabetes or adults that are 
healthy. Pre-existing diabetes in 
patients who are pregnant 
Intervention Low GI diet  Studies involving dietary supplements 
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Comparator higher GI diet 
Studies involving additional 
supplements 
Outcomes 
Primary outcome measures of interest: Cardio-
metabolic: total cholesterol, low density 
lipoprotein (LDL) cholesterol, high density 
lipoprotein (HDL) cholesterol, triglycerides. 
Secondary outcome measures of interest:  
Inflammatory parameters: C–reactive protein, 
Adiponectin and Interleukin–6 
Qualitative outcomes  
Types of Study: 
Quantitative 
Randomised controlled trials 
Observational studies  
Letters 
Comments 
Reviews 
Editorials 
 
Figure 1. Prisma flow chart showing the studies included. 
2.4. Quality Assessment and Risk of Bias of Included Studies 
The Critical Appraisal Skills Programme (CASP) checklist for randomised controlled trials [28] 
was used to evaluate the studies. In addition, the Cochrane risk of bias tool [29,30] was used to assess 
the methodological quality of the included studies. A grade (or score) was allocated to each trial on 
the basis of selection bias, performance bias, detection bias, attrition bias, and reporting bias. This 
process involved reviewing details about the similarity at baseline of the groups being compared, the 
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Full-text articles assessed for 
eligibility (n = 35) 
Records 
identified 
through PubMed 
Records identified 
through EMBASE 
(n = 644)  
Records identified 
through PsycINFO  
(n = 87) 
Records after de-duplication (n = 970) 
Records Screened 
(n = 35) 
Studies excluded using 
Abstracts and titles  
n = 935 
Records identified 
through reference 
lists (n = 7) 
n = 2 (Studies involving pregnant 
women with gestational and type 
2 diabetes in the same study) 
n = 13 (Studies with no outcomes 
of interest) 
n = 7 (Cross-over studies and 
difficulty with data extraction) 
n = 2 (Non randomised studies) 
n= 1 (Study with women at high 
risk of GDM) 
n = 25 
Studies included in Meta-
analysis (n = 9) 
Studies included in systematic 
review (n = 10) 
n = 1 (Quantitative data relating to 
outcomes of interest unavailable) n = 1 
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blindness of the outcome measurement and participants, the randomisation method, dropout rates, 
selective reporting, and compliance with the intervention. On the basis of this information, studies 
were categorised into three groups: (a) low risk of bias, (b) unclear risk of bias, and (c) high risk of 
bias. 
2.5. Data Extraction and Management 
Statistical Analysis 
Treatment effects were summarized as the weighted mean difference (WMD) with standard 
deviation by using the absolute change values from baseline to post-intervention for control and 
intervention groups. The meta-analysis was performed in stata (version 15.0, Stata Corp, College 
Station, TX, USA). Fixed-effects models were applied to estimate the overall weighted mean 
difference. 
All results were presented with a 95% confidence interval (CI) and displayed on a forest plot 
and table, and the null hypothesis of no effect was rejected at p ≤ 0.05. In addition to the forest plots, 
I2 statistics were assessed to quantify the degree of heterogeneity. Values <25% were considered to be 
low, 25%–50% moderate, and >50% high. Q statistics was also used to assess heterogeneity. The null 
hypothesis of homogeneity was rejected if p < 0.1, given the low power of the test [29]. 
2.6. Data Inclusion Decisions 
Gomes et al. [31] expressed their results as the median and interquartile ranges, which were 
converted to means and standard deviations [29]. In addition, for the meta-analysis, the units of 
measurements for the lipid parameters were converted to mmol/L, while for the inflammatory 
markers, they were converted to mg/L. The Grant et al. [32] study was not included in the meta-
analysis, as the information provided showed that there were no significant differences (p > 0.05) 
between the low GI and the higher GI groups in terms of lipids and inflammatory markers. However, 
these results were not expressed in quantitative terms. 
3. Results 
Ten studies were selected for the systematic review (Table 3), and nine studies were included in 
the meta-analysis (Table 4). In addition, while four of the studies were conducted in Canada, two 
were carried out in China and one study each was carried out in Brazil, Greece, Malaysia, and the 
USA.The total number of subjects in the eight studies included in the meta-analysis in patients with 
type 2 diabetes involved 394 participants in the low GI group and 388 participants in the higher GI 
group. There were 41 subjects in the low GI group compared with 42 participants in the higher GI 
group in the only study on women with GDM.  
Based on the systematic review (Tables 3 and 4) and meta-analysis, two distinct areas have been 
identified: the effect of a low GI diet on lipid profiles and the effect of a low GI diet on inflammatory 
parameters. 
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Table 3. The summary of studies selected for the review. 
Citation Country 
Type of 
Diabetes 
Length of 
Study 
Study 
Type Age (Years)  Sample Size 
Interventions/Glycemic Index 
(GI) Values Results/Conclusion 
Gomes et 
al. [31] 
Brazil 
Type 2 
diabetes 
1 month 
Parallel 
Design  
42.4 ± 5.1 n = 20 
Low GI diet v. higher GI diet 
(Mean ± SD) 
Baseline 
Higher GI: 66 ± 4 
Low GI: 63 ± 6 
Post-intervention 
Higher GI: 72 ± 3 
Low GI: 54 ± 4 
Serum non esterified fatty acid level increased in the 
higher GI group compared to the low GI group after 
intervention (p = 0.032). Low GI diet prevented the 
inflammatory responses induced by higher GI diet.  
Grant et 
al. [32] 
Canada GDM 
From 28 
weeks 
gestation 
until 
delivery 
Parallel 
Design 
Higher GI: 34 ± 1.1 
Low GI: 34 ± 0.1 
Low GI: n = 
23 
Higher GI: n 
= 24 
Higher GI v. Low GI (Mean ± SD) 
Higher GI: 58 ± 0.5  
Low GI: 49 ± 0.8 
The difference between the low GI and higher GI 
groups in respect of lipids and CRP were not 
statistically significant (p > 0.05). 
Ma et al. 
[33] 
China GDM 12–14 Weeks 
Parallel 
Design  
Higher GI: 30.0 ± 
3.5 
Low GI: 30.1 ± 3.8 
p = 0.901 
Higher GI: n 
= 42 
Low GL: n = 
41 
Higher GI v. Low GI (Mean ± SD) 
Baseline  
Higher GI: 56.1 ± 2.4 
Low GI: 56.0 ± 2.1  
Post-intervention 
Higher GI: 53.8 ± 2.5 
Low GI: 50.1 ± 2.2  
The increases in TC, TG and the decrease in HDL 
cholesterol were significantly lower (p < 0.05) in the 
low GI group compared with the higher GI group.  
Jenkins et 
al. [34] 
Canada 
Type 2 
diabetes 
6 months 
Parallel 
Design 
(Mean ± SD) 
High-cereal fibre 
diet = 61 ± 9 
Low-GI diet = 60 ± 
10 
210 
Low GI diet v. high-cereal fibre 
diet Mean (95% CI) 
Baseline  
Higher GI: 81.5 (80.4–82.7) 
Low GI: 80.8 (79.6–82.0) 
Post-intervention 
Higher GI: 83.5 (82.4–84.7) 
Low GI: 69.6 (67.7–71.4) 
HDL cholesterol increased by 1.7 mg/dL in the low 
GI group and decreased by −0.2 mg/dL in the higher 
GI group (p = 0.005). 
Reductions of the CRP were similar in the low GI 
and higher GI groups. 
Jenkins et 
al. [35] 
Canada 
Type 2 
diabetes 
3 months 
Parallel 
Design  
(Mean±SEM) 
High-wheat fibre 
diet: 61 ± 1.0 
Low-GI legume 
diet: 58 ± 1.3  
121 
Low GI legume diet v. high-
wheat fibre diet Mean (95% CI) 
Baseline  
Higher GI: 78 (77–80) 
Low GI: 80 (79–82) 
Post-intervention 
Higher GI: 82 (81–83) 
Low GI: 66 (64–67) 
Low GI legume produced significant decreases in 
TC (p < 0.001) and TG (p < 0.001) with no significant 
change in HDL cholesterol (p = 0.19). 
The relative reduction in TC and HDL cholesterol 
were greater in the low GI legume diet group 
compared with the higher GI diet group. No other 
lipid treatment differences were significant. 
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Ma et al. 
[36] 
USA 
Type 2 
diabetes 
12 months 
Parallel 
Design 
(Mean ± SD) 53.53 
± 8.40 
40 
Low GI diet v. American Diabetes 
Association diet (ADA) (Mean ± 
SEM) 
Baseline  
ADA: 82.03 ± 1.31 
Low GI: 79.35 ± 1.36  
Post-intervention 
ADA: 80.36 ± 1.40 
Low GI: 76.64 ± 1.46 
There were no significant differences between low 
GI and higher GI groups with respect to TC, HDL 
and TG. 
Wolever et 
al. [37] 
Canada 
Type 2 
diabetes 
12 months 
Parallel 
Design 
(Mean ± SEM) 
Higher GI diet: 
60.4 ± 1.1 
Low GI diet: 60.6 ± 
1.0  
162 
Low GI diet v. higher GI diet 
(Mean ± SEM) 
Baseline  
Higher GI: 61.5 ± 0.4 
Low GI: 60.3 ± 0.4 
Post-intervention 
Higher GI: 63.2 ± 0.4  
Low GI: 55.1 ± 0.4 
There were no significant effects for TC. With the 
low GI diet, mean triacylglycerol was 12% higher, 
HDL was 4% lower, the higher GI values were 
intermediate.  
The CRP with the low GI diet was 29% less than the 
higher GI diet (p < 0.05). 
Yusof et 
al. [38] 
Malaysi
a 
Type 2 
diabetes 
12 weeks 
Parallel 
Design 
Not data 104 
Low GI diet v. conventional 
carbohydrate exchange (CCE) 
(Mean ± SD) 
Baseline  
Higher GI: 64 ± 6 
Low GI: 63 ± 5 
Post-intervention 
Higher GI: 64 ± 5 
Low GI: 57 ± 6 
TG increased at week 4, then decreased at week 12 
in the Low GI group and this was reversed in the 
CCE group. Serum HDL cholesterol increased 
significantly in both groups over time, although no 
significant differences were found between the two 
groups. 
Argiana et 
al. [39] 
Greece 
Type 2 
diabetes 
12 weeks 
Parallel 
Design 
Control: 63.0 ± 1.3 
Low GI: 61.3 ± 1.4 
n = 61 Low GI diet v. Higher GI diet 
The differences between the low GI diet and control 
diet with respect to HDL cholesterol at the end of 
the study was statistically significant (p = 0.007). 
A significant decrease (p = 0.02) in CRP was found in 
participants in the low GI diet group and the 
differences between the low GI and the higher GI 
groups were significant (p = 0.007) after the study. 
Serum IL–6 and adiponectin did not differ 
significantly in both groups at week 0 and week 12. 
Cai et al. 
[40] 
China 
Type 2 
diabetes 
12 months 
Parallel 
Design 
56.7 ± 3.5 n = 130 Low GI diet v. Higher GI diet 
After intervention, the levels of CRP-reactive 
protein and IL–6 in the low GI diet were 
significantly lower than the control group (p < 0.05). 
Abbreviations: CCE (conventional carbohydrate exchange); Higher GI (Higher glycemic index); Low GI (Low glycemic index); n (Number); TC: total cholesterol; 
TG: triglyceride; CRP: C-reactive protein; IL–6: interleukin 6; v. (Versus).  
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Table 4. Cardio–metabolic and inflammatory parameters of studies included. 
Citation  Baseline Versus Post-Intervention HDL Cholesterol  LDL Cholesterol Total Cholesterol Triglyceride 
C–Reactive 
Protein Adiponectin Interleukin–6 
Gomes et 
al. [31] 
Baseline mg/dL 
Median 
(Minimum/Maxim
um) 
Post-intervention 
Higher GI: 43 (30/59)  
Low GI: 38 
(27.6/45.2) 
Higher GI: 40 (30/54)  
Low GI: 41 (24.5/47) 
No Data 
Higher GI: 210.1 
(180/273.5)  
Low GI: 200.4 
(123/248.1) 
Higher GI: 211 
(172/284)  
Low GI: 214.1 
(145/288.5) 
Higher GI: 180.2 
(88.7/287)  
Low GI: 195 
(68/372) 
Higher GI: 175.3 
(132/311.2)  
Low GI: 205.1 
(63/384.1) 
(mg/L) Higher GI: 
2.6 (0.8/7.3) 
Low GI: 2.7 
(0.5/5.5) 
Higher GI: 2.8 
(0.6/6.13)  
Low GI: 2.5 
(0.1/6.9) 
p = 0.44 
ng/mL Higher GI: 
30.9 (29.8/31.4 
Low GI: 30.1 
(29.4/31.3) 
Higher GI: 30.8 
(30.2/31.6) 
Low GI: 30.5 
(26.7/93) 
p = 0.74 
No Data 
Ma et al. 
[33] 
Baseline mmol/L 
(Mean ± SD) 
Post-intervention 
Higher GI: 1.96 ± 
0.39  
Low GI: 1.89 ± 0.33 
Higher GI: 1.85 ± 
0.36  
Low GI: 1.87 ± 0.34 
Higher GI: 2.13 ± 
0.60  
Low GI: 2.19 ± 0.58  
Higher GI: 2.16 ± 
0.81  
Low GI: 2.20 ± 0.54 
Higher GI: 5.74 ± 
0.74 
Low GL: 5.79 ± 
1.01 
Higher GI: 5.97 ± 
0.89  
Low GI: 5.96 ± 
1.02 
Higher GI: 2.20 ± 
0.60 
Low GI:2.67 ± 1.27 
Higher GI: 3.14 ± 
1.05  
Low GI: 3.09 ± 1.14  
No Data No Data No Data 
Jenkins et 
al. [34] 
Baseline mg/dL 
(Mean) 
Post-intervention 
Higher GI: 43.1 
Low GI: 41.9 
Higher GI: 42.8 
Low GI: 43.6 
Higher GI: 101.1 
Low GI: 96.9 
Higher GI: 101.3 
Low GI: 95.3 
Higher GI: 168.4 
Low GI: 164.3 
Higher GI: 168.4 
Low GI: 162.6 
Higher GI: 122.0 
Low GI: 128.1 
Higher GI: 122.2 
Low GI: 124.6 
Higher GI: 4.59 
Low GI: 4.62 
Higher GI: 2.82 
Low GI: 3.02 
No Data No Data 
Jenkins et 
al. [35] 
Baseline mg/dL 
(95% CI) 
Post-intervention 
Higher GI: 47 (44, 
50)  
Low GI: 43 (40, 46) 
Higher GI: 48 (45, 
52) 
Low GI: 43 (40, 45) 
Higher GI: 91 (81, 
101)  
Low GI: 84 (77, 92) 
Higher GI: 90 (81, 
99) 
Low GI: 81 (74, 89) 
Higher GI: 163 
(151, 174)  
Low GI: 158 (147, 
168) 
Higher GI: 161 
(150, 172) 
Low GI: 149 (139, 
160) 
Higher GI: 124 
(104, 145) 
Low GI: 149 (125, 
173) 
Higher GI: 115 (96, 
133) 
Low GI: 128 (107, 
148) 
No Data No Data No Data 
Ma et al. 
[36] 
Baseline mg/dL 
(Mean ± SEM) 
Post-intervention 
Higher GI: 42.95 ± 
2.26 
Low GI: 45.42 ± 2.38 
Higher GI: 44.29 ± 
2.30 
Low GI: 47.53 ± 2.43 
Higher GI: 88.95 ± 
7.52 
Low GI: 93.16 ± 8.07 
Higher GI: 71.49 ± 
7.81 
Low GI: 94.50 ± 8.32 
Higher GI: 168.10 
± 9.06 
Low GI: 175.58 ± 
9.53 
Higher GI: 149.71 
± 9.35 
Low GI: 173.63 ± 
0.06 
p = 0.09 
* Higher GI: 5.05 
(0.14) 
Low GI: 4.99 (0.15) 
Higher GI: 4.93 
(0.15) 
Low GI: 4.90 (0.16) 
No Data No Data No Data 
Nutrients 2019, 11, 1584 10 of 18 
Wolever 
et al. [37] 
Baseline mmol/L 
(Mean ± SEM) 
Post-intervention 
Higher GI: 1.14 ± 
0.05 
Low GI: 1.21 ± 0.03 
Higher GI: 1.19 ± 
0.03 
Low GI: 1.16 ± 0.03 
Higher GI: 2.82 ± 
0.13 
Low GI: 3.02 ± 0.13 
Higher GI: 3.0 ± 0.08 
Low GI: 2.92 ± 0.05  
Higher GI: 4.86 ± 
0.16 
Low GI: 5.09 ± 
0.13  
Higher GI: 5.04 ± 
0.08 
Low GI: 5.04 ± 
0.08 
Higher GI: 2.07 ± 
0.15 
Low GI: 1.87 ± 0.10 
Higher GI: 2.0 ± 
0.07 
Low GI: 2.17 ± 0.07 
**Higher GI: 3.34 
(2.56, 4.26) 
Low GI: 2.64 (1.89, 
3.70) 
Higher GI: 2.75 
(2.33, 3.24) 
Low GI: 1.95 (1.68, 
2.27) 
No Data No Data 
Yusof et 
al. [38] 
Baseline mmol/L 
(Mean ± SEM) 
Post-intervention 
Higher GI: 1.18 ± 
0.34 
Low GI: 1.08 ± 0.30 
Higher GI: 1.21 ± 
0.05 
Low GI: 1.14 ± 0.04  
Higher GI: 2.78 ± 
0.67 
Low GI: 2.78 ± 0.67 
Higher GI: 2.93 ± 
0.14  
Low GI: 2.67 ± 0.11  
Higher GI: 4.56 ± 
0.80 
Low GI: 4.54 ± 
0.75 
Higher GI: 4.80 ± 
0.16 
Low GI: 4.54 ± 
0.12  
Higher GI: 1.35 ± 
0.53 
Low GI: 1.5 ± 0.47 
Higher GI: 1.46 ± 
0.08 
Low GI: 1.59 ± 0.10 
No Data No Data No Data 
Argiana et 
al. [39] 
Baseline mg/dL 
(Mean ± SEM) 
Post-intervention 
Higher GI: 46.4 ± 1.8 
Low GI: 43.1 ± 1.3 
Higher GI: 46.1 ± 1.7 
Low GI: 43.3 ± 1.2 
Higher GI: 104.9 ± 
5.1 
Low GI: 107.0 ± 5.5 
Higher GI: 104.2 ± 
5.2  
Low GI: 97.2 ± 6.2 
Higher GI: 176.6 ± 
5.2 
Low GI: 173.9 ± 
6.4 
Higher GI: 175.8 ± 
5.2 
Low GI: 167.0 ± 
4.1 
Higher GI: 126.5 ± 
10.8 
Low GI: 119.2 ± 
11.6 
Higher GI: 127.5 ± 
10.3  
Low GI: 122 ± 9.3 
*** Higher GI: 2.1 ± 
0.5  
Low GI: 4.4 ± 1.2 
Higher GI: 2.8 ± 0.6 
Low GI: 3.0 ± 0.8 
*** Higher GI: 7.4 ± 
1.6 Low GI: 12.2 ± 
3.4 
Higher GI: 8.3 ± 
2.1 Low GI: 12.5 ± 
1.5 
**** Higher GI: 1.3 
± 0.2 
Low GI: 1.4 ± 0.3 
Higher GI: 2.0 ± 0.5 
Low GI: 1.3 ± 0.2 
Cai et al. 
[40] 
Baseline mg/L 
(Not stated 
whether Mean or 
SD) 
Post-intervention 
No Data No Data No Data No Data 
Higher GI: 8.03 ± 
0.72  
Low GI: 8.04 ± 0.75 
Higher GI: 5.01 ± 
0.32  
Low GI: 3.68 ± 0.29 
No Data 
**** Higher GI: 
12.26 ± 1.57 
Low GI: 12.29 ± 
1.44 
Higher GI: 9.01 ± 
0.83 
Low GI: 7.97 ± 0.86 
Abbreviations: CCE (conventional carbohydrate exchange); Higher GI (Higher glycemic index); Low GI (Low glycemic indexn (Number); TC: total cholesterol; TG: 
triglyceride; CRP: C-reactive protein; IL–6: interleukin 6. * mmol/L (Natural Logarithm); ** mg/L (Mean, 95% CIs); *** µg/mL (Mean ± SEM); **** pg/mL (Mean ± 
SEM); v. (Versus). 
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3.1. Evaluation of the Risk of Bias of the Studies Selected 
Most of the studies demonstrated either a low risk of bias or an unclear risk of bias in all the 
domains evaluated (selection bias, performance bias, detection bias, attrition bias, and reporting bias) 
(Figure 2). However, Jenkins et al. [34] showed high risk of bias in the area of selection bias (Figure 
3). 
 
Figure 2. A summary risk of bias graph of included studies. 
 
Figure 3. A risk of bias graph for each included study. 
3.2. The Effect of a Low GI Diet on Lipid Profile 
Grant et al. [32] found no significant differences (p > 0.05) between the low GI group compared 
to the higher GI group, with respect to the lipid profile in women with GDM (Table 3). In their study, 
Ma et al. [33] observed that the increases in total cholesterol (0.12 versus 0.23 mmol/L) and triglyceride 
(0.41 versus 0.56 mmol/L), and the decrease in HDL cholesterol (−0.01 versus −0.11), were significantly 
lower (p < 0.05) than the higher GI group in women with GDM (Table 4). 
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In patients with type 2 diabetes, the results of the meta-analysis showed no significant 
differences (p > 0.05) between the low GI and higher GI groups with respect to HDL with a mean 
difference of 0.00 mmol/L (−0.02, 0.02) and LDL cholesterol with a mean difference of −0.14 mmol/L 
(−0.37, 0.09) (Figures 4 and 5, respectively). 
 
Figure 4. A forest plot showing the effects of a low GI diet on HDL cholesterol (mmol/L). 
 
Figure 5. A forest plot showing the effect of a low GI diet on LDL cholesterol (mmol/L). 
In addition, the findings from the meta-analysis found no significant difference (p > 0.05) 
between the two groups in relation to the total cholesterol which decreased by a mean of −0.08 
mmol/L (−0.31, 0.16) (Figure 6) in the low GI group. The results showed that there was a significant 
difference (p = 0.027) with respect to triglycerides, which increased by a mean of 0.06 mmol/L (0.01, 
0.11) in patients with type 2 diabetes in the higher GI group (Figure 7). 
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Figure 6. A forest plot depicting the effect of a low GI diet on Total Cholesterol (mmol/L). 
 
Figure 7. A forest plot depicting the effect of a low GI diet on Triglyceride (mmol/L). 
3.3. The Effect of a Low GI Diet on Inflammatory Parameters 
According to Grant et al. [32], there was no significant difference (p > 0.05) between the low GI 
and higher GI groups in relation to the C–reactive protein in women with GDM. In patients with type 
2 diabetes, Gomes et al. [31] and Cai et al. [40] found that a low GI diet can reduce or prevent the 
inflammatory responses induced by a high GI diet. In addition, a low GI diet has been shown to 
reduce C–reactive protein levels significantly compared to a high GI diet [37,39]. 
With respect to serum interleukin–6 and adiponectin, Argiana et al. [39] did not find significant 
differences in both groups between week 0 and week 12 in patients with type 2 diabetes. The results 
of the meta-analysis did not show significant differences (p > 0.05) between low GI and higher GI 
diets with respect to adiponectin and C-reactive protein in patients with type 2 diabetes (Table 5). 
However, a significant difference (p < 0.001) was observed between the two groups in relation to 
interleukin–6 (Table 5), with the low GI diet decreasing interleukin–6 by a mean of −1.01 mg/L (−1.55, 
−0.48). A meta-analysis was not conducted for the patients with GDM with respect to inflammatory 
parameters due to the limited number of studies. 
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Table 5. Results of a meta-analysis of the effect of a low GI diet on inflammatory parameters. 
Outcomes 
Patients with Type 2 Diabetes 
N Studies Weighted Mean Difference (95% CI) mg/L p-Value I
2 % 
Interleukin–6 2 −1.01 (−1.55, −0.48) 0.001 0.0 
C–eactive Protein 5 −0.32 (−1.17, 0.53) 0.467 0.0 
Adiponectin 2 0.01 (−0.00, 0.03) 0.072 0.0 
4. Discussion 
The results of the two studies [32,33] that evaluated the effects of low GI diets on lipid profiles 
in women with GDM were not consistent. While Grant et al. [32] did not find significant differences 
(p > 0.05) between the low GI and higher GI groups in relation to lipids, Ma et al. [33] found significant 
differences (p < 0.05) between the two groups with respect to total cholesterol, triglycerides, and HDL 
cholesterol. On the other hand, the results of the meta-analysis showed that there were no significant 
differences (p > 0.05) between the low GI diet and higher GI group with respect to total cholesterol, 
HDL, and LDL cholesterol in patients with type 2 diabetes (although the difference was statistically 
significant (p < 0.05) in relation to triglycerides, with higher GI diet increasing triglyceride levels). 
The differences observed between the effects of a low GI in patients with GDM compared to patients 
with type 2 diabetes in some of the metabolites may due to the limited number of studies in the 
current review and the differences in the pathophysiology of both conditions. In a previous meta-
analysis, Fleming and Godwin [24] revealed that a low GI diet may help lower total cholesterol and 
LDL cholesterol. In addition, Goff et al. [13] found that low GI diets reduced total and LDL cholesterol 
and had no effect on HDL cholesterol and triglycerides. It is possible that the differences between the 
current review and the previous reviews in relation to some of the metabolites may be due to the 
participants included in the studies. While this review was based only on patients with GDM and 
type 2 diabetes, the earlier reviews were based on the general population [24] or included participants 
without diabetes [13]. 
The results of the effect of a low GI diet on inflammatory markers were variable in the studies 
selected in patients with GDM. However, the results of the meta-analysis showed that differences 
between low GI and higher GI groups were only significant (p < 0.05) in relation to interleukin–6, 
which decreased in the low GI group in patients with type 2 diabetes. These results are discussed 
below. 
4.1. The Effect of a Low GI Diet on Lipid Profile 
There appears to be controversy regarding the role of low GI diets in the prevention of 
cardiovascular diseases. The effect of GI on total cholesterol, LDL, and HDL cholesterol is not quite 
clear [39,41]. For example, in women with GDM, Grant et al. [32] reported no significant differences 
(p > 0.05) between the low GI and higher GI groups with respect to the lipids in women with GDM. 
However, Ma et al. [33] found that low GI diets improved blood lipids. 
In patients with type 2 diabetes, Gomes et al. [31] found that a low GI diet reduced body fat. In 
the study by Jenkins et al. [34], it was observed that HDL cholesterol increased by 1.7 mg/dL in the 
low GI group and decreased by −0.2 mg/dL in the higher GI group (p = 0.005). In contrast, Wolever et 
al. [37] noted that HDL cholesterol was 4% lower in the low GI group, while the higher GI values 
were intermediate. Other studies [35,36,38] demonstrated no significant difference between the low 
GI and higher GI groups in relation to HDL cholesterol. 
According to Jenkins et al. [35], low GI legumes produced significant decreases in total 
cholesterol level (p < 0.001) in patients with type 2 diabetes. The relative reduction in total cholesterol 
level was greater in the low GI legume diet group compared with the higher GI group [35]. However, 
Ma et al. [36] and Wolever et al. [37] did not find a significant difference between low GI and higher 
GI diets with respect to the total cholesterol in patients with type 2 diabetes. 
Jenkins et al. [35] demonstrated that a low GI legume produced significant decreases in 
triglycerides (p < 0.001) in patients with type 2 diabetes. Decreases in triglycerides in the low GI group 
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were also reported by Yusof et al. [38], although Wolever et al. [37] showed increased levels of 
triglycerides in the low GI group. On the other hand, Ma et al. [36] found no significant difference 
between low GI and higher GI with respect to triglycerides. 
The mechanism by which dietary GI influences blood lipids has not been entirely elucidated 
[42]. This may explain the differences in the findings of the various studies. However, it has been 
suggested that high GI diets increase non esterified fatty acid concentrations after intervention 
compared to baseline, and increased levels of non-esterified fatty acids can cause beta cell 
dysfunction, insulin resistance, and reduced glucose uptake [31]. In other words, elevated levels of 
blood glucose, insulin, and free fatty acids following a high GI diet can induce insulin resistance, 
which could lead to increased triglyceride, a greater inflammatory response, and a decrease in HDL 
cholesterol [43,44]. 
Hyperinsulinaemia and insulin resistance are significantly correlated to dyslipidaemia and 
contribute to the changes in the plasma lipid profile [45]. Therefore, the potential effects of a low GI 
diet on cardiometabolic parameters may be caused by a reduction of hyperglycaemia, 
hyperinsulinaemia and levels of free fatty acids, which could lead to a reduced risk of insulin 
resistance, beta cell dysfunction, dyslipidaemia, and inflammatory response [45,46]. 
4.2. The Effect of a Low GI Diet on Inflammatory Parameters 
Based on the findings of the meta-analysis in relation to the inflammatory parameters, low GI 
diets significantly decreased (p < 0.05) levels of interleukin-6 compared with the higher GI diets in 
patients with type 2 diabetes. Differences between the two groups were not statistically significant (p 
> 0.05) with respect to C-reactive proteins. The mechanism for this finding, with respect to 
interleukin-6, may due to hyperglycaemia in the higher GI group, which induces the release of 
inflammatory cytokines from monocytes [47]. Furthermore, the exposure of endothelial cells to 
varying levels of glucose concentration can increase the risk of oxidative stress and apoptosis and 
thus lead to the production of pro-inflammatory cytokines [39,48,49]. The results of this review 
confirm the findings of a previous study by Juanola-Falgaroma et al. [50], which found that subjects 
allocated a low GI diet showed significantly higher decreases in interleukin–6 after intervention. 
This review has both clinical and public health implications in terms of our understanding of 
the role low GI diets in the management of cardiometabolic and inflammatory parameters in patients 
with diabetes. 
5. Limitations 
Although a total of nine studies were included in the meta-analysis, this number was limited by 
the two sub-groups of GDM and type 2 diabetes. More studies in each of the sub-groups would have 
further enhanced the wider application of the findings of this review. In addition, the lack of a 
consensus on what constitutes a low GI diet, and the variation in the GI levels of dietary interventions 
in the studies included, may have impacted the analysis of the findings of this review. 
6. Conclusions 
This systematic review and meta-analysis have demonstrated that there were no significant 
differences (p > 0.05) between low GI and higher GI diets in relation to total cholesterol, HDL, and 
LDL cholesterol in patients with type 2 diabetes. However, a significant difference (p < 0.05) was 
observed between the two groups with respect to triglycerides in patients with type 2 diabetes. The 
results of the effect of a low GI diet on the lipid profile in patients with GDM were not consistent. 
With respect to the inflammatory parameters, the low GI diet significantly decreased interleukin–6 
in patients with type 2 diabetes than the higher GI diet. More studies are needed in this area of 
research. 
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